|
What are the latest figures on the priorix market’s size and projected CAGR?
The priorix market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to the inclusion of priorix in the national immunization schedule, recurrent outbreaks of diseases, focus on combination vaccines, growing demand for cost-effective vaccines, and high efficacy of priorix. The priorix market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to rising adoption of WHO recommendations on immunization, rising school-based vaccination, expansion of retail pharmacy-based immunization services, focus on regional manufacturing, and increase in international funding. Major trends in the forecast period include partnerships for vaccine distribution, AI-based surveillance on immunization gaps, a shift towards decentralized vaccine manufacturing, the use of digital tools for vaccination tracking, and the development of temperature-stable vaccine formulation. Get Your Free Sample of The Global Priorix Market Report: Which Market drivers have played a significant role in driving the priorix market? The rise in the prevalence of mumps is expected to propel the priorix market going forward. Mumps is a contagious viral infection characterized by painful swelling of the salivary glands, particularly the parotid glands, located below the ears. The rise in mumps prevalence is driven by waning immunity from childhood vaccinations, insufficient vaccine coverage, and increased outbreaks in crowded settings such as schools and colleges. Priorix is used to prevent mumps by providing active immunization against the mumps virus as part of a combination vaccine. It stimulates the immune system to produce antibodies, reducing infection risk and curbing outbreaks. For instance, in December 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, the total number of mumps cases in the US in 2022 was 386, which reached 436 in 2023. Therefore, the rise in the prevalence of mumps drives the priorix market. What are the key segments within the priorix market? 1) By Formulation: Lyophilized (Freeze-dried); Liquid Order your report now for swift delivery Which key players are shaping the priorix market? Major companies operating in the priorix market are GSK plc Which transformative trends will shape the priorix market landscape? The key trend in the priorix market is the regulatory approval of priorix for preventing measles, mumps, and rubella. This approval offers an additional vaccination option against these highly contagious diseases, which remain significant global health threats. For instance, in June 2022, GSK plc, a UK-based pharmaceutical and biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has approved Priorix, a live vaccine for the prevention of measles, mumps, and rubella (MMR) in individuals aged 12 months and older. Priorix is administered as a two-dose series, with the first dose given between 12 to 15 months of age and the second dose at 4 to 6 years of age. It can also be used as a second dose for individuals who have received the first dose of another MMR vaccine. How do regional factors impact the priorix market, and which region is the largest contributor? North America was the largest region in the priorix market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the priorix market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. What Does The Priorix Market Report 2025 Offer? The priorix market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities. Priorix is a combination vaccine used to protect against three infectious diseases namely measles, mumps, and rubella (MMR). It contains live, attenuated viruses of these diseases, which stimulate the immune system to provide immunity. Typically administered as a subcutaneous or intramuscular injection, Priorix is given in two doses, the first at 12–15 months of age and the second around 4–6 years, depending on national immunization schedules. Purchase the exclusive report now to unlock valuable market insights: With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead. Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making. Contact Us: Follow Us On: |
Priorix Market Report 2025 – Priorix Market Share And Growth By 2034
